女性不妊症(Women Infertility):治療薬開発パイプライン動向(世界、2015年上半期版)

◆英語タイトル:Women Infertility - Pipeline Review, H1 2015
◆商品コード:GMDHC6133IDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2015年1月30日
◆ページ数:214
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、世界における女性不妊症(Women Infertility)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・女性不妊症(Women Infertility)の概要
・女性不妊症(Women Infertility)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・女性不妊症(Women Infertility)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・女性不妊症(Women Infertility)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・女性不妊症(Women Infertility)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Women Infertility – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Women Infertility – Pipeline Review, H1 2015’, provides an overview of the Women Infertility’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Women Infertility
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Women Infertility and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Women Infertility pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Women Infertility
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Women Infertility Overview 10
Therapeutics Development 11
Pipeline Products for Women Infertility – Overview 11
Pipeline Products for Women Infertility – Comparative Analysis 12
Women Infertility – Therapeutics under Development by Companies 13
Women Infertility – Therapeutics under Investigation by Universities/Institutes 18
Women Infertility – Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Unknown Stage Products 23
Women Infertility – Products under Development by Companies 24
Women Infertility – Products under Investigation by Universities/Institutes 29
Women Infertility – Companies Involved in Therapeutics Development 30
AbbVie Inc. 30
Actavis plc 31
Addex Therapeutics Ltd 32
AlphaMab Co., Ltd 33
APAvadis Biotechnologies Srl 34
ASKA Pharmaceutical Co., Ltd. 35
Astellas Pharma Inc. 36
AstraZeneca PLC 37
Bayer AG 38
Crinetics Pharmaceuticals, Inc. 39
Dong-A Socio Group 40
Dongkook Pharmaceutical Co., Ltd. 41
EffRx Pharmaceuticals S.A. 42
ElexoPharm GmbH 43
EndoCeutics, Inc. 44
Euroscreen S.A. 45
Evotec AG 46
Ferring International Center S.A. 47
Finox AG 48
Forendo Pharma Oy 49
GlaxoSmithKline plc 50
Glycotope GmbH 51
Isifer AB 52
Kissei Pharmaceutical Co., Ltd. 53
Lipicard Technologies Limited 54
Merck & Co., Inc. 55
Merck KGaA 56
Neurocrine Biosciences, Inc. 57
Nora Therapeutics, Inc. 58
ObsEva SA 59
Orphagen Pharmaceuticals, Inc. 60
Pantec Biosolutions AG 61
PharmaEssentia Corporation 62
Philogen S.p.A. 63
PlasmaTech Biopharmaceuticals, Inc. 64
PregLem SA 65
Reliance Life Sciences Pvt. Ltd. 66
Repros Therapeutics Inc. 67
SK Chemicals Co., Ltd. 68
Takeda Pharmaceutical Company Limited 69
Teva Pharmaceutical Industries Limited 70
Trophogen, Inc. 71
ValiRx Plc 72
Zydus Cadila Healthcare Limited 73
Women Infertility – Therapeutics Assessment 74
Assessment by Monotherapy Products 74
Assessment by Combination Products 75
Assessment by Target 76
Assessment by Mechanism of Action 79
Assessment by Route of Administration 81
Assessment by Molecule Type 83
Drug Profiles 85
(anastrozole + levonorgestrel) – Drug Profile 85
acolbifene hydrochloride + GnRH agonist + prasterone – Drug Profile 86
ADX-68692 – Drug Profile 87
AKP-501 – Drug Profile 88
ASP-1707 – Drug Profile 89
AZD-4901 – Drug Profile 90
barusiban – Drug Profile 91
BAY-1026153 – Drug Profile 92
BAY-1128688 – Drug Profile 93
bentamapimod – Drug Profile 94
Biosimilar 4 for Acute Myocardial Infarction and Infertility – Drug Profile 95
Biosimilar 5 for Infertility – Drug Profile 96
Biosimilar 6 for Infertility – Drug Profile 97
Biosimilar 7 for Infertility and Oncology – Drug Profile 98
choriogonadotropin alfa – Drug Profile 99
choriogonadotropin alfa biosimilar – Drug Profile 100
corifollitropin alfa – Drug Profile 101
DR-2011 – Drug Profile 103
Drug to Inhibit C-Jun for Endometriosis – Drug Profile 104
Drug to Target RERG for Endometriosis – Drug Profile 105
Drugs for Endometriosis – Drug Profile 106
Drugs for Endometriosis and Uterine Fibroids – Drug Profile 107
elagolix sodium – Drug Profile 108
Endole – Drug Profile 110
epelsiban besylate – Drug Profile 111
ESN-364 – Drug Profile 113
EVE-104 – Drug Profile 114
FE-999310 – Drug Profile 115
follitropin alfa – Drug Profile 116
follitropin alfa – Drug Profile 117
follitropin alfa (recombinant) – Drug Profile 118
follitropin delta – Drug Profile 120
FP-5677 – Drug Profile 121
FSH-GEX – Drug Profile 122
goserelin biosimilar – Drug Profile 124
Isifera – Drug Profile 125
kisspeptin – Drug Profile 126
KLH-2109 – Drug Profile 127
KN-015 – Drug Profile 128
LM-001 – Drug Profile 129
LM-002 – Drug Profile 130
LT-6121 – Drug Profile 131
menotropins – Drug Profile 132
metformin hydrochloride – Drug Profile 133
Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis – Drug Profile 134
NCE-403 – Drug Profile 135
NT-100 – Drug Profile 136
OBE-001 – Drug Profile 137
Oral Fertility Drugs – Drug Profile 138
PEG-FSH – Drug Profile 139
Peptides for Cancer and Endometriosis – Drug Profile 140
Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis – Drug Profile 141
PGL-1001 – Drug Profile 142
PGL-2001 – Drug Profile 143
PGL-3001 – Drug Profile 144
progesterone nanoparticles – Drug Profile 145
Progesterone Second Generation – Drug Profile 146
Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome – Drug Profile 147
Recombinant Protein to Agonize Luteinizing Hormone for Infertility – Drug Profile 148
relugolix – Drug Profile 149
RTPR-013 – Drug Profile 150
Small Molecule to Agonize FSHR for Infertility – Drug Profile 151
Small Molecule to Antagonize FSH Receptor for Women’s Health – Drug Profile 152
Small Molecules for Female Infertility – Drug Profile 153
Small Molecules to Antagonize GnRH for Endometriosis, Uterine Fibroids, PCOS and Oncology – Drug Profile 154
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis – Drug Profile 155
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing’s Disease – Drug Profile 156
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis – Drug Profile 157
Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers – Drug Profile 158
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis – Drug Profile 159
Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome – Drug Profile 160
Small Molecules to Inhibit Plasminogen Activator Inhibitor-1 for Thromboembolic Disease, PCOS and Alopecia – Drug Profile 161
SR-16234 – Drug Profile 162
Synthetic Peptide for Metabolic Syndrome and Polycystic Ovarian Syndrome – Drug Profile 163
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology – Drug Profile 164
telapristone acetate – Drug Profile 165
Tetravil – Drug Profile 168
TR-4401 – Drug Profile 170
triptorelin – Drug Profile 171
triptorelin pamoate biosimilar – Drug Profile 172
VAL-201 – Drug Profile 173
vilaprisan – Drug Profile 174
VPE-001 – Drug Profile 175
Women Infertility – Recent Pipeline Updates 176
Women Infertility – Dormant Projects 195
Women Infertility – Discontinued Products 199
Women Infertility – Product Development Milestones 201
Featured News & Press Releases 201
Appendix 207
Methodology 207
Coverage 207
Secondary Research 207
Primary Research 207
Expert Panel Validation 207
Contact Us 207
Disclaimer 208

[List of Tables]
Number of Products under Development for Women Infertility, H1 2015 17
Number of Products under Development for Women Infertility - Comparative Analysis, H1 2015 18
Number of Products under Development by Companies, H1 2015 20
Number of Products under Development by Companies, H1 2015 (Contd..1) 21
Number of Products under Development by Companies, H1 2015 (Contd..2) 22
Number of Products under Development by Companies, H1 2015 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2015 25
Comparative Analysis by Late Stage Development, H1 2015 26
Comparative Analysis by Clinical Stage Development, H1 2015 27
Comparative Analysis by Early Stage Development, H1 2015 28
Comparative Analysis by Unknown Stage Development, H1 2015 29
Products under Development by Companies, H1 2015 30
Products under Development by Companies, H1 2015 (Contd..1) 31
Products under Development by Companies, H1 2015 (Contd..2) 32
Products under Development by Companies, H1 2015 (Contd..3) 33
Products under Development by Companies, H1 2015 (Contd..4) 34
Products under Investigation by Universities/Institutes, H1 2015 35
Women Infertility - Pipeline by AbbVie Inc., H1 2015 36
Women Infertility - Pipeline by Actavis plc, H1 2015 37
Women Infertility - Pipeline by Addex Therapeutics Ltd, H1 2015 38
Women Infertility - Pipeline by AlphaMab Co., Ltd, H1 2015 39
Women Infertility - Pipeline by APAvadis Biotechnologies Srl, H1 2015 40
Women Infertility - Pipeline by ASKA Pharmaceutical Co., Ltd., H1 2015 41
Women Infertility - Pipeline by Astellas Pharma Inc., H1 2015 42
Women Infertility - Pipeline by AstraZeneca PLC, H1 2015 43
Women Infertility - Pipeline by Bayer AG, H1 2015 44
Women Infertility - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015 45
Women Infertility - Pipeline by Dong-A Socio Group, H1 2015 46
Women Infertility - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2015 47
Women Infertility - Pipeline by EffRx Pharmaceuticals S.A., H1 2015 48
Women Infertility - Pipeline by ElexoPharm GmbH, H1 2015 49
Women Infertility - Pipeline by EndoCeutics, Inc., H1 2015 50
Women Infertility - Pipeline by Euroscreen S.A., H1 2015 51
Women Infertility - Pipeline by Evotec AG, H1 2015 52
Women Infertility - Pipeline by Ferring International Center S.A., H1 2015 53
Women Infertility - Pipeline by Finox AG, H1 2015 54
Women Infertility - Pipeline by Forendo Pharma Oy, H1 2015 55
Women Infertility - Pipeline by GlaxoSmithKline plc, H1 2015 56
Women Infertility - Pipeline by Glycotope GmbH, H1 2015 57
Women Infertility - Pipeline by Isifer AB, H1 2015 58
Women Infertility - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 59
Women Infertility - Pipeline by Lipicard Technologies Limited, H1 2015 60
Women Infertility - Pipeline by Merck & Co., Inc., H1 2015 61
Women Infertility - Pipeline by Merck KGaA, H1 2015 62
Women Infertility - Pipeline by Neurocrine Biosciences, Inc., H1 2015 63
Women Infertility - Pipeline by Nora Therapeutics, Inc., H1 2015 64
Women Infertility - Pipeline by ObsEva SA, H1 2015 65
Women Infertility - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015 66
Women Infertility - Pipeline by Pantec Biosolutions AG, H1 2015 67
Women Infertility - Pipeline by PharmaEssentia Corporation, H1 2015 68
Women Infertility - Pipeline by Philogen S.p.A., H1 2015 69
Women Infertility - Pipeline by PlasmaTech Biopharmaceuticals, Inc., H1 2015 70
Women Infertility - Pipeline by PregLem SA, H1 2015 71
Women Infertility - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2015 72
Women Infertility - Pipeline by Repros Therapeutics Inc., H1 2015 73
Women Infertility - Pipeline by SK Chemicals Co., Ltd., H1 2015 74
Women Infertility - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 75
Women Infertility - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 76
Women Infertility - Pipeline by Trophogen, Inc., H1 2015 77
Women Infertility - Pipeline by ValiRx Plc, H1 2015 78
Women Infertility - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 79
Assessment by Monotherapy Products, H1 2015 80
Assessment by Combination Products, H1 2015 81
Number of Products by Stage and Target, H1 2015 83
Number of Products by Stage and Mechanism of Action, H1 2015 86
Number of Products by Stage and Route of Administration, H1 2015 88
Number of Products by Stage and Molecule Type, H1 2015 90
Women Infertility Therapeutics - Recent Pipeline Updates, H1 2015 182
Women Infertility - Dormant Projects, H1 2015 201
Women Infertility - Dormant Projects (Contd..1), H1 2015 202
Women Infertility - Dormant Projects (Contd..2), H1 2015 203
Women Infertility - Dormant Projects (Contd..3), H1 2015 204
Women Infertility - Discontinued Products, H1 2015 205
Women Infertility - Discontinued Products (Contd..1), H1 2015 206

[List of Figures]
Number of Products under Development for Women Infertility, H1 2015 17
Number of Products under Development for Women Infertility - Comparative Analysis, H1 2015 18
Number of Products under Development by Companies, H1 2015 19
Number of Products under Investigation by Universities/Institutes, H1 2015 24
Comparative Analysis by Late Stage Development, H1 2015 26
Comparative Analysis by Clinical Stage Development, H1 2015 27
Comparative Analysis by Early Stage Products, H1 2015 28
Assessment by Monotherapy Products, H1 2015 80
Assessment by Combination Products, H1 2015 81
Number of Products by Top 10 Targets, H1 2015 82
Number of Products by Stage and Top 10 Targets, H1 2015 82
Number of Products by Top 10 Mechanism of Actions, H1 2015 85
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 85
Number of Products by Top 10 Routes of Administration, H1 2015 87
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 87
Number of Products by Top 10 Molecule Types, H1 2015 89
Number of Products by Stage and Top 10 Molecule Types, H1 2015 89

【掲載企業】

AbbVie Inc.
Actavis plc
Addex Therapeutics Ltd
AlphaMab Co., Ltd
APAvadis Biotechnologies Srl
ASKA Pharmaceutical Co., Ltd.
Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
Crinetics Pharmaceuticals, Inc.
Dong-A Socio Group
Dongkook Pharmaceutical Co., Ltd.
EffRx Pharmaceuticals S.A.
ElexoPharm GmbH
EndoCeutics, Inc.
Euroscreen S.A.
Evotec AG
Ferring International Center S.A.
Finox AG
Forendo Pharma Oy
GlaxoSmithKline plc
Glycotope GmbH
Isifer AB
Kissei Pharmaceutical Co., Ltd.
Lipicard Technologies Limited
Merck & Co., Inc.
Merck KGaA
Neurocrine Biosciences, Inc.
Nora Therapeutics, Inc.
ObsEva SA
Orphagen Pharmaceuticals, Inc.
Pantec Biosolutions AG
PharmaEssentia Corporation
Philogen S.p.A.
PlasmaTech Biopharmaceuticals, Inc.
PregLem SA
Reliance Life Sciences Pvt. Ltd.
Repros Therapeutics Inc.
SK Chemicals Co., Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
Trophogen, Inc.
ValiRx Plc
Zydus Cadila Healthcare Limited

★調査レポート[女性不妊症(Women Infertility):治療薬開発パイプライン動向(世界、2015年上半期版)] (コード:GMDHC6133IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[女性不妊症(Women Infertility):治療薬開発パイプライン動向(世界、2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆